The preliminary decision, if finalized, would allow facilities running the Verax Platelet PGD test to bill for Medicare outpatient reimbursement of platelet components tested with PGD, according to a news release.
CMS’ preliminary decision establishes a Healthcare Common Procedure Coding System modifier for “Rapid bacterial tested” for use with existing HCPCS codes for platelets for outpatient reimbursement purposes. This modifier could be used across the broad variety
“We are incredibly pleased with this decision. When finalized, this will have a significantly positive impact on the practice of transfusion medicine,” Verax CEO Jim Lousararian said in a prepared statement. “We view this as a major development both in terms of blood safety policy and acknowledging the economic value of testing the nation’s platelet supply.”
CMS will hold a public meeting June 1 to take public comment and discussion on its preliminary decision as the next step towards final adoption.
More articles on finance and revenue cycle management:
What is drawing Cleveland Clinic, Mayo Clinic and other AMCs to Florida?
Opponents come out against proposal to charge Ohio Medicaid enrollees
For-profit hospital stock report: Week of May 2-6
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
